Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)

CONCLUSIONS: Anlotinib was tolerated in Chinese refractory mCRC patients. Although OS did not reach significant difference, anlotinib still provided clinical benefits by substantially prolonged PFS in these patients.IMPLICATIONS FOR PRACTICE: In this randomized clinical trial that included 419 patients with refractory metastatic colorectal cancer, substantial prolonged in progression-free survival was noted in patients who received anlotinib compared with those given placebo. Improvements on objective response rate and disease control rate was also observed in anlotinib group. However, overall survival was similar between the two groups. In a word, in third-line or above treatment of Chinese patients with refractory metastatic colorectal cancer, anlotinib provided clinical benefit by significantly prolonged progression-free survival.PMID:34105207 | DOI:10.1002/onco.13857

Source: The Oncologist - June 9, 2021 Category: Cancer & Oncology Authors: Yihebali Chi Yongqian Shu Yi Ba Yuxian Bai Baoli Qin Xiuwen Wang Jianping Xiong Nong Xu Helong Zhang Jianfeng Zhou Jianming Xu Ying Cheng Jifeng Feng Chunhong Hu Yigui Chen Zhendong Chen Jufeng Wang Chengxue Dang Jianhong Wang Yiye Wan Yong Tang Donglin W Source Type: research